KeyBanc Starts Castle Biosciences (CSTL) at Overweight

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. META
6. BA
7. SPY
8. INTC
9. JBLU
10. HOOD

Go back to KeyBanc Starts Castle Biosciences (CSTL) at Overweight

Castle Biosciences Inc. (CSTL) Misses Q3 EPS by 12c

November 9, 2020 4:57 PM EST

Castle Biosciences Inc. (NASDAQ: CSTL) reported Q3 EPS of ($0.23), $0.12 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $15.2 million versus the consensus estimate of $14.99 million.

The Castle team made significant progress on our strategic growth initiatives in the third quarter, said Derek Maetzold, president and chief executive officer of Castle Biosciences. We also returned to year-over-year volume growth in DecisionDx®-Melanoma report volume, our current lead revenue driver, despite a... More